

# APPLICATION OF PIMONIDAZOLE – MALIGNANT TISSUE

## 3. Tumors – Clinical

### Bladder

1. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. *Br J Cancer* 2003; 89: 1290-7.
2. Hoskin PJ, Sibtain A, Daley FM, Saunders MI, Wilson GD. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. *Radiother Oncol* 2004; 72: 159-68.

### Breast

1. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. *Lab Invest* 2002; 82: 911-8.
2. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. *Blood* 2004; 104: 2224-34.
3. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. *Am J Pathol* 2005; 167: 627-35.
4. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. *Int J Cancer* 2005; 117: 701-8.
5. Westbury CB, Pearson A, Nerurkar A, et al. Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. *Br J Radiol* 2007; 80: 934-8.
6. Wennemers M, Bussink J, Scheijen B, et al. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. *Breast Cancer Res* 2011; 13: R82.

### Colorectal

1. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? *Strahlenther Onkol* 2003; 179: 801-11.
2. van Laarhoven H, Lok J, Rijpkema M, et al. Relation between dynamic gadolinium uptake rate, tumor vasculature and tumor hypoxia in human colorectal liver metastases. *Proc Intl Soc Mag Reson Med*; 2004; 2004. p. 148.

3. van Laarhoven HW, de Geus-Oei LF, Wiering B, et al. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. *Radiology* 2005; 237: 181-8.
4. Goethals L, Debucquoy A, Perneel C, et al. Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. *Int J Radiat Oncol Biol Phys* 2006; 65: 246-54.
5. van Laarhoven HW, Kaanders JH, Lok J, et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. *Int J Radiat Oncol Biol Phys* 2006; 64: 473-82.
6. Greijer AE, Delis-van Diemen PM, Fijneman RJ, et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. *Virchows Arch* 2008; 452: 535-44.
7. Verstraete M, Debucquoy A, Devos E, et al. Investigation of possible endogenous hypoxia markers in colorectal cancer. *Int J Radiat Biol* 2012.

### **Lung ( Non-small cell)**

1. Mandeville HC, Ng QS, Daley FM, et al. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. *Radiology* 2012; 264: 581-9.

### **Prostate**

1. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. *Int J Radiat Oncol Biol Phys* 2006; 65: 91-9.
2. Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. *Int J Radiat Oncol Biol Phys* 2007; 68: 1065-71.

### **Squamous Cell Carcinoma**

1. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. *Int J Radiat Oncol Biol Phys* 1997; 37: 897-905.
2. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. *Cancer Res* 1998; 58: 3765-8.
3. Haustermans K, Hofland I, Van de Pavert L, et al. Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. *Radiother Oncol* 2000; 55: 325-33.

4. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. *Clin Cancer Res* 2000; 6: 855-62.
5. Wijffels KI, Kaanders JH, Rijken PF, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. *Br J Cancer* 2000; 83: 674-83.
6. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. *Int J Radiat Oncol Biol Phys* 2001; 49: 569-74.
7. Hoebbers FJ, Janssen HL, Olmos AV, et al. Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Why do hypoxic cells behave badly? *Eur J Nucl Med Mol Imaging* 2002; 29: 1206-11.
8. Janssen HL, Haustermans KM, Sprong D, et al. HIF-1alpha, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. *Int J Radiat Oncol Biol Phys* 2002; 54: 1537-49.
9. Azuma Y, Chou SC, Lininger RA, Murphy BJ, Varia MA, Raleigh JA. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. *Clin Cancer Res* 2003; 9: 4944-452.
10. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. *Radiother Oncol* 2003; 67: 3-15.
11. Chou SC, Azuma Y, Varia MA, Raleigh JA. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. *Br J Cancer* 2004; 90: 728-35.
12. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. *Clin Cancer Res* 2005; 11: 20-7.
13. Hoogsteen IJ, Peeters WJ, Marres HA, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. *Radiother Oncol* 2005; 76: 213-8.
14. De Schutter H, Barbe B, Spaepen M, et al. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. *Radiother Oncol* 2006; 80: 143-50.
15. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. *Radiother Oncol* 2006; 79: 288-97.
16. Silva P, Homer JJ, Slevin NJ, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. *Clin Otolaryngol* 2007; 32: 337-45.

17. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. *Oral Oncol* 2007; 44: 335-44.
18. Bussink J, van der Kogel AJ, Kaanders JH. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome: in regard to Evans et al. (*Int J Radiat Oncol Biol Phys* 2007;69:1024-1031). *Int J Radiat Oncol Biol Phys* 2008; 70: 1616.
19. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. *Oral Oncol* 2008; 44: 335-44.
20. Donaldson SB, Betts G, Bonington SC, et al. Perfusion Estimated with Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely with Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. *Int J Radiat Oncol Biol Phys* 2011; 81: 1176-83.
21. Nijkamp MM, Hoogsteen IJ, Span PN, et al. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. *Radiother Oncol* 2011; 101: 165-70.
22. Betts GN, Eustace A, Patiar S, et al. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. *Eur J Cancer* 2012.
23. Hoogsteen IJ, Marres HA, van den Hoogen FJ, et al. Expression of EGFR Under Tumor Hypoxia: Identification of a Subpopulation of Tumor Cells Responsible for Aggressiveness and Treatment Resistance. *Int J Radiat Oncol Biol Phys* 2012; 84: 807-14.
24. Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy. *Semin Radiat Oncol* 2012; 22: 119-27.